Biora Therapeutics, Inc. (NASDAQ:BIOR) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET

Company Participants

Chuck Padala – Managing Director-LifeSci Advisors

Adi Mohanty – Chief Executive Officer

Eric d'Esparbes – Chief Financial Officer

Conference Call Participants

Julian Harrison – BTIG

Sahil Kazmi – B. Riley Securities

Operator

Thank you for standing by. This is the conference operator. Welcome to the Biora Therapeutics Fourth Quarter 2022 Financial Results Conference Call. As a reminder, all participants are in listen-only mode and the conference is being recorded. After the presentation, there will be an opportunity to ask questions. [Operator Instructions]

I would now like to turn the conference over to Chuck Padala, Managing Director with LifeSci Advisors, Biora's Investor Relations firm. Please, Chuck, go ahead.

Chuck Padala

Thank you, operator. Good afternoon, and welcome to the Biora Therapeutics fourth quarter 2022 corporate update and financial results conference call. Joining me on the call are Adi Mohanty, Chief Executive Officer; and Eric d'Esparbes, Chief Financial Officer.

Before I turn the call over to Mr. Mohanty, I would like to remind you that today's call will include forward-looking statements within the meaning of the federal securities laws, including, but not limited to, the types of statements identified as forward-looking in our annual report on Form 10-K that we will file later today and our subsequent reports filed with the SEC, which are all available on our website in the Investors section.

These forward-looking statements represent our views only as of the date of this call and involve substantial risks and uncertainties, including many that are beyond our control. Please note that actual results could differ materially from those projected in any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements as well as risks related to our business, please see the company's periodic reports filed with the SEC.

With that, I will now turn the call over to Adi Mohanty, CEO of Biora Therapeutics.

Adi Mohanty

Thanks, Chuck, and thank you, everyone, for joining us. During the fourth quarter, we continued to focus on executing our development plans for our targeted therapeutics program, completing the execution phase of our tox study and making progress on our IND-enabling activities. We also presented detailed data from our third device function study at the Crohn's & Colitis Congress in January of this year. In our systemic therapeutics program, we made significant progress on the evolution of our next-generation device. We recently shared top line bioavailability results that were more than double our target levels. These results have been well received by our collaborators and already, one of them has agreed to progress to testing their molecule with our systemic therapeutics platform.